NCT03431285.
Trial name or title | Ketamine for acute painful crisis in sickle cell disease patients |
Methods |
Allocation: randomized Controlled: active comparator Blinding: triple Arm: 3 arm, parallel groups Centre: single Study duration: 1 January 2018 (recruiting, ongoing) |
Participants |
Inclusion criteria: known diagnosis of sickle cell disease based on sickle cell tests and haemoglobin electrophoresis; acute onset of painful crises, defined as having an onset within 7 days Exclusion criteria: healthy volunteers; other comorbidities; allergies to study medication; pregnancy or breastfeeding Baseline characteristics N: 264 participants, still recruiting Gender: men and women Ages: 18–60 years Setting and location: Dammam University, Saudi Arabia |
Interventions |
Treatment group: morphine Control group: ketamine Other group: standard intravenous hydration |
Outcomes |
Primary outcomes
Secondary outcomes
|
Starting date | 1 January 2018 |
Contact information | Mohammed SS Alshahrani, MD, Dammam, Eastern, Saudi Arabia, 31952 |
Notes |